Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BG-68501,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
Ensem Therapeutics: Milestone Achieved with CDK2 Inhibitor for Solid Tumors
Details : BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor, which is being evaluated for the treatment of HR+/HER2 solid tumors including breast, ovarian, and Small Cell Lung Cancer.
Brand Name : BG-68501
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2024
Lead Product(s) : BG-68501,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ETX-197
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : BeiGene
Deal Size : $1,330.0 million
Deal Type : Licensing Agreement
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
Details : Under the agreement, BeiGene will acquire an exclusive global license to an Investigational New Drug application-ready, ETX-197, an oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Brand Name : ETX-197
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 21, 2023
Lead Product(s) : ETX-197
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : BeiGene
Deal Size : $1,330.0 million
Deal Type : Licensing Agreement
Details : Proceeds will be used to further advance the company's Kinetic Ensemble platform and accelerate R&D pipeline. Biomolecules such as proteins and RNAs are in constant motion, with an ensemble of conformations that govern their functions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2022
LOOKING FOR A SUPPLIER?
Reset All
